DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS This update of the GO29365 study shows significant survival benefit with pola + BR vs BR alone in R/R, transplant ineligible DLBCL. In the randomization arms, median progression-free survival was 9.2 vs 3.7 months and median overall survival was 12.4 vs 4.7 months for the pola + BR arm vs the BR arm. In the extension cohort, the OR rate was 41.5%, and the CR rate was 38.7%; PFS and OS were 6.6 months and 12.5 months, respectively.
Peer-influenced content. Sources you trust. No registration required. This is HCN.